EN DE
STOCK COMPARISON

Vista Pharmaceuticals vs Jiangsu Hengrui Pharma Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Vista Pharmaceuticals (VISTAPH) and Jiangsu Hengrui Pharma Co (1276) compare, as of Aug 21, 2026.

As of Aug 21, 2026, Fair Value Calculator sees Jiangsu Hengrui Pharma Co as the less overvalued of the two: Vista Pharmaceuticals trades at ₹6.30 versus a fair value of ₹3.02 (-52%), while Jiangsu Hengrui Pharma Co trades at HK$49.66 versus HK$33.59 (-32%).
Vista Pharmaceuticals
VISTAPH.BSE · INR · Health Care
-52%
upside to fair value
overvalued
Price₹6.30
Fair Value₹3.02
Quality24/100
Jiangsu Hengrui Pharma Co
1276.HK · HKD · Healthcare
-32%
upside to fair value
overvalued
PriceHK$49.66
Fair ValueHK$33.59
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Vista PharmaceuticalsJiangsu Hengrui Pharma Co
Valuation
—P/E (TTM)41.0×
0.05×P/S (TTM)11.79×
—P/B5.63×
—EV/EBITDA35.8×
—Dividend yield0.4%
—Dividend per shareHK$0.20
Profitability
-89%Net margin25%
-132%Operating margin32%
-14%Return on equity15%
-8%Return on assets9%
Growth
-5%Revenue growth (YoY)13%
75.2%Avg. growth/yr (3Y)13.2%
33.6%Avg. growth/yr (5Y)2.6%
Balance & size
0.05×Debt / equity—
$5MMarket cap$49B
mixedGrowth qualityhealthy

Jiangsu Hengrui Pharma Co leads: 3 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Vista Pharmaceuticalsof which business quality 24 · market factors 23 Jiangsu Hengrui Pharma Coof which business quality 68 · market factors 26
ProfitabilityMargins and returns on capital today
0
63
Quality GrowthAre margins and returns improving?
3
46
CashflowEarnings quality: real cash, not paper profit
0
82
Fin. StrengthBalance sheet, leverage, solvency risk
47
100
InvestmentDisciplined investing over empire-building
77
28
Low VolatilityCalm price path (market factor)
50
70
MomentumPrice trend over the last 3–12 months (market factor)
15
12
52W MomentumDistance to the 52-week high (market factor)
5
0
Net IssuanceBuybacks instead of dilution
40
63

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Vista Pharmaceuticals

Asset-Based₹3.97

1 of 1 models see the stock below the current price.

Jiangsu Hengrui Pharma Co

DCF ModelsHK$40.78
Earnings-BasedHK$21.65
MultiplesHK$26.01
Asset-BasedHK$6.99
Growth DCFHK$40.93
Economic ProfitHK$20.41
Growth EarningsHK$30.97

22 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Vista Pharmaceuticals
Bear ₹2.25Fair Value ₹3.02Bull ₹4.50
₹6.30 = current price (white tick)
Jiangsu Hengrui Pharma Co
Bear HK$25.19Fair Value HK$33.59Bull HK$41.04
HK$49.66 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Vista Pharmaceuticals · Health Care

Quality score24 · bottom 25%
Fair value upside-52% · below median

Jiangsu Hengrui Pharma Co · Healthcare

Quality score67 · Top 25%
Fair value upside-32% · above median

Bottom line

As of Aug 21, 2026, Fair Value Calculator sees Jiangsu Hengrui Pharma Co as the less overvalued of the two: Vista Pharmaceuticals trades at ₹6.30 versus a fair value of ₹3.02 (-52%), while Jiangsu Hengrui Pharma Co trades at HK$49.66 versus HK$33.59 (-32%).

Jiangsu Hengrui Pharma Co has the higher quality score (67/100).

See the full analysis →
Vista Pharmaceuticals · Jiangsu Hengrui Pharma Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Vista Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Pharma Co

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs PDD Holdings
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.